{"transactions":[{"id":793726,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-04T20:01:13.000Z","date":"2026-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":8567,"price":1.28,"value":10965.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":618942,"source":{"system":"sec-edgar","filing":"0001104659-26-054858","document":"tm2613475-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926054858/tm2613475-1_4seq1.xml","form_type":"4"}},{"id":804406,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T20:18:30.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.13,"value":11300.0,"ownership":{"direct":true},"balance_after":627509,"source":{"system":"sec-edgar","filing":"0001104659-26-045511","document":"tm2612247-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926045511/tm2612247-3_4seq1.xml","form_type":"4"}},{"id":896622,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T21:16:26.000Z","date":"2026-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1560,"price":1.12,"value":1747.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":617509,"source":{"system":"sec-edgar","filing":"0001104659-26-017068","document":"tm266602-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926017068/tm266602-2_4seq1.xml","form_type":"4"}},{"id":917611,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T22:27:19.000Z","date":"2026-02-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":26921,"price":1.03,"value":27728.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":619069,"source":{"system":"sec-edgar","filing":"0001104659-26-011074","document":"tm265419-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926011074/tm265419-2_4seq1.xml","form_type":"4"}},{"id":917610,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T22:27:19.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon\nsettlement."}],"balance_after":645990,"source":{"system":"sec-edgar","filing":"0001104659-26-011074","document":"tm265419-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926011074/tm265419-2_4seq1.xml","form_type":"4"}},{"id":960857,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-22T21:10:23.000Z","date":"2025-12-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":9360,"price":1.5,"value":14040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of PSUs."}],"balance_after":445990,"source":{"system":"sec-edgar","filing":"0001104659-25-123721","document":"tm2534021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925123721/tm2534021-1_4seq1.xml","form_type":"4"}},{"id":960856,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-12-22T21:10:23.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares earned upon the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on February 14, 2024. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. The remaining 50% of the total number of shares subject to the PSUs vested on December 18, 2025."}],"balance_after":455350,"source":{"system":"sec-edgar","filing":"0001104659-25-123721","document":"tm2534021-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925123721/tm2534021-1_4seq1.xml","form_type":"4"}},{"id":1078344,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-31T20:23:52.000Z","date":"2025-07-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":9360,"price":0.6702,"value":6273.072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of PSUs."}],"balance_after":425350,"source":{"system":"sec-edgar","filing":"0001062993-25-013357","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299325013357/form4.xml","form_type":"4"}},{"id":1078343,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-07-31T20:23:52.000Z","date":"2025-07-29","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares earned upon the vesting of performance stock units (\"PSUs\") granted to the Reporting Person on February 14, 2024. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. 50% of the total number of shares subject to the PSUs vested on July 29, 2025."}],"balance_after":434710,"source":{"system":"sec-edgar","filing":"0001062993-25-013357","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299325013357/form4.xml","form_type":"4"}},{"id":1161089,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-02T21:53:52.000Z","date":"2025-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":9692,"price":0.4472,"value":4334.2624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":404710,"source":{"system":"sec-edgar","filing":"0001062993-25-008394","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299325008394/form4.xml","form_type":"4"}},{"id":1263639,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-18T21:28:23.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1723,"price":0.5901,"value":1016.7423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":414402,"source":{"system":"sec-edgar","filing":"0001062993-25-002703","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299325002703/form4.xml","form_type":"4"}},{"id":1284600,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-04T21:12:56.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":295000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":416125,"source":{"system":"sec-edgar","filing":"0001062993-25-001620","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299325001620/form4.xml","form_type":"4"}},{"id":1528040,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-03T20:07:05.000Z","date":"2024-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":8699,"price":1.95,"value":16963.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":121125,"source":{"system":"sec-edgar","filing":"0001062993-24-009329","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299324009329/form4.xml","form_type":"4"}},{"id":1633486,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-20T21:13:35.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on February 15, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through the applicable vesting dates."}],"balance_after":20000,"derivative":{"exercise_price":1.98,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001062993-24-003651","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299324003651/form4.xml","form_type":"4"}},{"id":1633485,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-20T21:13:35.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":129824,"source":{"system":"sec-edgar","filing":"0001062993-24-003651","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299324003651/form4.xml","form_type":"4"}},{"id":1905988,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-03T20:20:46.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":109824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on May 1, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through the applicable vesting dates."}],"balance_after":109824,"derivative":{"exercise_price":1.65,"expiration_date":"2033-05-01","underlying":"Common Stock","underlying_shares":109824},"source":{"system":"sec-edgar","filing":"0001062993-23-010091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299323010091/form4.xml","form_type":"4"}},{"id":1905987,"issuer":{"id":6792,"kind":"organization","name":"COGNITION THERAPEUTICS INC"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-03T20:20:46.000Z","date":"2023-05-01","kind":"grant","planned":false,"acquired":true,"shares":109824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement."}],"balance_after":109824,"source":{"system":"sec-edgar","filing":"0001062993-23-010091","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1455365/000106299323010091/form4.xml","form_type":"4"}},{"id":2612706,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-05T17:26:37.000Z","date":"2021-08-05","kind":"disposition_to_issuer","acquired":false,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of May 4, 2021, by and among Chiasma, Inc. (the \"Company), Amryt Pharma plc (\"Parent\"), and Acorn Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent (\"Merger Sub\") pursuant to which Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving as an indirect wholly owned subsidiary of Parent effective as of August [5], 2021 (the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each option to purchase Shares (each, a \"Company Option\") that was outstanding and unexercised, immediately prior to the Effective Time, whether or not vested shall, by virtue of the Merger Agreement, ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase Parent ADSs (each an \"Assumed Stock Option\") shall be equal to (i) the number of Shares subject to each Company Option immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, rounded down, if necessary, to the nearest whole number of Parent ADSs, and such Assumed Stock Option shall have an exercise price per Parent ADS (rounded up to the nearest cent) equal to (a) the exercise price per Share otherwise purchasable pursuant to such Company Option divided by (b) the Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":3.95,"underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-21-050010","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121050010/doc4.xml","form_type":"4"}},{"id":2901817,"issuer":{"id":136487,"kind":"organization","name":"CHIASMA, INC","symbol":"CHMA"},"owners":[{"id":49941,"kind":"person","name":"Doyle John Brendan","position":1,"cik":"0001840738","reported_name":"Doyle John Brendan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-20T17:33:46.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest over a four-year period as follows: 25% will vest on the first anniversary of the date of grant and the remaining 75% will vest in equal monthly installments for the following 36 months, provided continued employment with the Company on each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":3.95,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-21-004402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339469/000120919121004402/doc4.xml","form_type":"4"}}]}